ClearPoint Neuro (CLPT) CEO settles 84,829 RSUs, covers taxes in shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. CEO and President Joseph Burnett settled 84,829 restricted stock units, receiving the same number of common shares upon vesting. To cover tax withholding obligations, 43,161 common shares were delivered back to ClearPoint Neuro at $11.53 per share, which is not an open-market sale. Following these transactions, Burnett holds 95,900 common shares directly and an additional 193,231 common shares indirectly through the Joseph M. Burnett Trust dated 10/20/2022, where he serves as trustee.

Insider Trade Summary

84,829 shares exercised/converted

Mixed 4 txns

Insider BURNETT JOSEPH

Role CEO and President

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	84,829	$0.00	--
Exercise	Common Stock	84,829	$0.00	--
Tax Withholding	Common Stock	43,161	$11.53	$498K
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 84,828 shares (Direct); Common Stock — 139,061 shares (Direct); Common Stock — 193,231 shares (Indirect, See footnote)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.

Form 4 Insider Transactions: What Each Field Means →

03/16/2026 - 02:51 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BURNETT JOSEPH

(Last)

(First)

(Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH

92075

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/12/2026		M		84,829	A	⁽¹⁾	139,061	D
Common Stock	03/12/2026		F		43,161⁽²⁾	D	$11.53	95,900	D
Common Stock								193,231	I	See footnote⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	03/12/2026		M			84,829	⁽¹⁾	⁽¹⁾	Common Stock	84,829	⁽¹⁾	84,828	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

3. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.

	/s/ Danilo D'Alessandro, by Power of Attorney for Joseph M. Burnett	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did ClearPoint Neuro (CLPT) report for Joseph Burnett?

ClearPoint Neuro reported that CEO Joseph Burnett settled 84,829 restricted stock units into common shares. In connection with this vesting, 43,161 common shares were delivered back to the company to satisfy tax withholding obligations, rather than sold in the open market.

How many ClearPoint Neuro (CLPT) shares does CEO Joseph Burnett now hold directly?

After the reported transactions, CEO Joseph Burnett directly holds 95,900 shares of ClearPoint Neuro common stock. These holdings reflect the net result of restricted stock unit settlement and shares delivered to the company for tax withholding on the vesting.

What was the size of the restricted stock unit vesting for ClearPoint Neuro (CLPT) CEO?

Joseph Burnett had 84,829 restricted stock units settle into the same number of ClearPoint Neuro common shares. Each unit represented a contingent right to one share that converted on its scheduled vesting date, as described in the footnote to the filing.

Why were 43,161 ClearPoint Neuro (CLPT) shares delivered to the company?

The 43,161 ClearPoint Neuro common shares were delivered to the company to satisfy applicable tax withholding obligations tied to the vesting of restricted stock. This tax-withholding disposition, at a price of $11.53 per share, is not an open-market sale by the CEO.

Does Joseph Burnett hold any ClearPoint Neuro (CLPT) shares indirectly?

Yes. In addition to his direct holdings, 193,231 ClearPoint Neuro common shares are owned by the Joseph M. Burnett Trust dated 10/20/2022. The filing states these shares are owned indirectly by Joseph Burnett in his capacity as trustee of the trust.

What type of transaction code was used for the ClearPoint Neuro (CLPT) RSU settlement?

The restricted stock unit settlement used transaction code M, indicating exercise or conversion of a derivative security. A separate transaction with code F covered delivery of 43,161 shares to ClearPoint Neuro to pay tax liabilities related to the restricted stock vesting.